Milnacipran: In fibromyalgia

Drugs

Volumn 70, Issue 1, 2010, Pages 99-108

  Chwieduk, Claudine M ^a   McCormack, Paul L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CLOMIPRAMINE; DIGOXIN; FLUOXETINE; LITHIUM; LORAZEPAM; MILNACIPRAN; MONOAMINE OXIDASE INHIBITOR; SAVELLA; UNCLASSIFIED DRUG; WARFARIN;

AREA UNDER THE CURVE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DISTRIBUTION VOLUME; DIZZINESS; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSURIA; EJACULATION DISORDER; ERECTILE DYSFUNCTION; FATIGUE; FIBROMYALGIA; GASTROESOPHAGEAL REFLUX; HEADACHE; HEART PALPITATION; HEART RATE; HOT FLUSH; HUMAN; HYPERHIDROSIS; HYPERTENSION; INSOMNIA; LIBIDO DISORDER; MAXIMUM PLASMA CONCENTRATION; MICTURITION; MIGRAINE; NAUSEA; NONHUMAN; PAIN ASSESSMENT; PERIPHERAL EDEMA; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; PROSTATITIS; QUESTIONNAIRE; REVIEW; SCORING SYSTEM; SCROTAL PAIN; SCROTAL SWELLING; SEROTONIN SYNDROME; SIDE EFFECT; SINGLE DRUG DOSE; SUICIDAL BEHAVIOR; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URETHRAL PAIN; URINARY HESITANCY; URINARY TRACT INFECTION; URINE RETENTION; VOMITING; XEROSTOMIA;

ANIMALS; BRONCHODILATOR AGENTS; COGNITION DISORDERS; CYCLOPROPANES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FIBROMYALGIA; HUMANS; META-ANALYSIS AS TOPIC; MUSCLE RELAXANTS, CENTRAL; MUSCLE, SKELETAL; NAUSEA; NOREPINEPHRINE; PAIN; PAIN MEASUREMENT; PATIENT COMPLIANCE; PATIENT SATISFACTION; PLACEBOS; SEX FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 73349114903     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11202810-000000000-00000     Document Type: Review

References (35)

1. American College of Rheumatology. Fibromyalgia (fact sheet) [online]. Available from URL: http://www.rheumatology. org/public/factsheets/diseases-and- conditions/fibromyalgia. pdf [Accessed 2009 Jul 29]
2. Spaeth M, Briley M. Fibromyalgia: a complex syndrome requiring a multidisciplinary approach. Hum Psycho-pharmacol Clin Exp 2009; 24 Suppl.: S3-10
3. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Arthritis Rheum 1990; 33 (2): 160-172
4. Katz RS, Wolfe F, Michaud K. Fibromyalgia diagnosis: a comparison of clinical, survey, and American College of Rheumatology criteria. Arthritis Rheum 2006; 54 (1): 169-176
5. Lawson K. Treatment options and patient perspectives in the management of fibromyalgia: future trends. Neuro-psych Dis Treat 2008; 4 (6): 1059-1071
6. Stahl SM. Fibromyalgia: pathways and neurotransmitters. Hum Psychopharmacol Clin Exp 2009; 24 Suppl.: S11-7
7. Buckhardt CS, Goldenberg D, Crofford L, et al. Guideline for the management of fibromyalgia syndrome pain in adults and children. [online]. Available from URL: http:// www.guideline.gov/summary/summary.aspx?ss=15doc- id=7298nbr=4342 [Accessed 2009 Jul 29]
8. Lyseng-Williamson KA, Siddiqui MA. Pregabalin: a review of its use in fibromyalgia. Drugs 2008; 68 (15): 2205-2223
9. Curran MP. Duloxetine: in patients with fibromyalgia. Drugs 2009; 69 (9): 1217-1227
10. Forest Pharmaceuticals Inc. Savella® (milnacipran HCl) tablets: US prescribing information [online]. Available from URL: http://www.frx.com/pi/ Savella-pi.pdf[Accessed 2009 Jun 22]
11. Spencer CM, Wilde MI. Milnacipran: a review of its use in depression. Drugs 1998 Sep; 56 (3): 405-427
12. Moret C, Charveron M, Finberg JP, et al. Biochemical profile of midalcipran (F2207), 1-phenyl-1-diethyl-aminocarbonyl-2-aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug. Neuropharmacology 1985; 24 (12): 1211-1219
13. Hindmarch I, Rigney U, Stanley N, et al. Pharmaco-dynamics of milnacipran in young and elderly volunteers. Br J Clin Pharmacol 2000 Feb; 49: 118-125
14. Poirier MF, Galinowski A, Amado I, et al. Double-blind comparative study of the action of repeated administration of milnacipran versus placebo on cognitive functions in healthy volunteers. Hum Psychopharmacol Clin Exp 2004; 19: 1-7
15. Caron J, Libersa C, Hazard JR, et al. Acute electrophysiological effects of intravenous milnacipran, a new antidepressant agent. Eur Neuropsychopharmacol 1993 Dec; 3: 493-500
16. Ingvar M, Petzke F, Marcus H, et al. Precuneus contrast distinguishes milnacipran from placebo: an fMRI study in fibromyalgia patients [abstract no. 857.19/HH2]. Presented at the 38th Annual Meeting for the Society for Neuro-science; 2008 Nov 15-19; Washington, DC
17. Pae C-U, Marks DM, Shah M, et al. Milnacipran: beyond a role of antidepressant. Clin Neuropharmacol 2009; 32 (6): 355-363
18. Mainguy Y. Functional magnetic resonance imagery (fMRI) in fibromyalgia and the response to milnacipran. Hum Psychopharmacol Clin Exp 2009; 24 Suppl.: S19-23
19. Mochizucki D. Serotonin and noradrenaline reuptake inhibitors in animal models of pain. Hum Psychopharmacol Clin Exp 2004; 19 Suppl.: S15-9
20. Arnold LM, Palmer RH, Hufford MR, et al. Milnacipran's effect on body weight by baseline BMI: results across 3 randomized, double-blind, placebo-controlled fibromyalgia trials. Presented at the 73rd Annual American College of Rheumatology Meeting; 2009 Oct 17-21; Philadelphia (PA)
21. Mease PJ, Clauw DJ, Gendreau RM, et al. The efficacy and safety of milnacipran for treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. J Rheumatol 2009 Feb; 36 (2): 398-409
22. Clauw DJ, Mease P, Palmer RH, et al. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther 2008 Nov; 30 (11): 1988-2004
23. Arnold LM, Gendreau RM, Spera A, et al. Milnacipran 100mg/day in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Poster presented at the 73rd Annual Scientific American College of Rheumatology Meeting; 2009 Oct 16-21; Philadelphia (PA)
24. Paris BL, Ogilvie BW, Scheinkienig JA, et al. In vitro inhibition and induction of human liver cytochrome P450 enzymes by milnacipran. Drug Metab Disp 2009; 37 (10): 2045-2054
25. Puozzo C, Rostin M, Montastruc JL, et al. Absolute bioavailability study of midalcipran (F 2207) in volunteers. In: Third European Congress of Biopharmaceutics and Pharmacokinetics Proceedings; 1987 Apr 21-24; Freiburg, Switzerland, 59-68
26. Puozzo C, Filaquier C, Briley M. Plasma levels of F 2207, midalcipran, a novel antidepressant, after single oral administration in volunteers. Br J Clin Pharmacol 1985; 20: 291P
27. Puozzo C, Leonard BE. Pharmacokinetics of milnacipran in comparison with other antidepressants. Int Clin Psycho-pharmacol 1996 Sep; 11 (Suppl. 4): 15-27
28. Puozzo C, Lens S, Reh C, et al. Lack of interaction of milnacipran with the cytochrome P450 isoenzymes frequently involved in the metabolism of antidepressants. Clin Phar-macokinet 2005; 44 (9): 977-988
29. Branco J, Bragee G, Zachrisson O, et al. Milnacipran for the treatment of fibromyalgia syndrome: a European multicenter, double-blind, placebo-controlled trial [abstract no. P.8.a.014]. Eur Neuropsychopharmacol 2008 Aug; 18 Suppl. 4: S574-5
30. Pierre Fabre Medicament. A multicentre trial to determine the efficacy and safety of milnacipran in the treatment of fibromyalgia syndrome [ClinicalTrials.gov identifier NCT00436033]. US National Institutes of Health, Clinical Trials.gov [online]. Availavle from URL: http://www. clinicaltrials.gov
31. Vitton O, Gendreau M, Gendreau J, et al. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol 2004 Oct; 19 Suppl. 1: S27-35
32. Gendreau RM, Thorn MD, Gendreau JF, et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol 2005 Oct; 32 (10): 1975-1985
33. Nagaoka S, Ohno M, Sekiguchi A. An open-label clinical trial of milnacipran in fibromyalgia syndrome with co-morbid depressive symptoms. Int JPsych Clin Pract 2004; 8 (1): 47-51
34. Bennett R. The fibromyalgia impact questionnaire (FIQ): a review of its development, current version, operating characteristics and uses. Clin Exp Rheumatol 2005; 23 Suppl. 39: S154-62
35. Mease P, Palmer RH, Rao S, et al. Improvements in fibro-myalgia symptoms are sustained for 1 year with milnacipran treatment: results from a dose-controlled, extension study [abstract no. 583]. Arthritis Rheum 2008; 58 (9 Suppl.): S383